Dynamic 3D-MR mammography: is there a benefit of sophisticated evaluation of enhancement curves for clinical routine?
The purpose of the study was to compare standard analysis with pharmacokinetic analysis of time-intensity curves in dynamic three-dimensional (3D) MR mammography (MRM) for their capability of differentiating benign from malignant disease. Dynamic MRM of the whole breast was performed at 1.0 T using an axial fast low-angle shot (FLASH) 3D sequence. For the standard evaluation, the enhancement of the first minute (E1) and the slope of enhancement from minute 2 to 10 (SE2-10) were calculated. For pharmacokinetic analysis, the amplitude of enhancement (A), distribution time (t21), and elimination time (tel) were computed. Sixty-two histologically verified lesions were evaluated. The standard evaluation methods yielded a highly significant difference between benign and malignant disease for E1 (P = .0008) and SE2-10 (P = .0001). The pharmacokinetic parameters gained similarly significant P values (A, P = .0014; t21, P = .0024; tel, P = .0001). Both standard and pharmacokinetic analysis concordantly discriminated between benign and malignant lesions in discriminant analysis. Compared with standard analysis, a pharmacokinetic analysis of time-intensity curves is not beneficial for routine clinical diagnosis.
Müller-Schimpfle
M
M
Department of Diagnostic Radiology, University of Tbingen, Germany.
Ohmenhäuser
K
K
Sand
J
J
Stoll
P
P
Claussen
C D
CD
D000293:Adolescent; D000328:Adult; D000368:Aged; D001940:Breast / Q000473:pathology; D001941:Breast Diseases / Q000175:diagnosis*; D001943:Breast Neoplasms / Q000175:diagnosis*; D003287:Contrast Media; D003937:Diagnosis, Differential; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008327:Mammography / Q000379:methods*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA